Clinical Research Of Maintenance Therapy With Dendritic Cells-Cytokine-induced Killer Cells In Patients With Advanced Non-small Cell Lung Cancer

Objective: The incidence and development of cancer are closely related todysfunction of immune function. Immune system cannot identify and removemalignant and mutant cells, which causes tumor cells to escape from surveillance andclearance of immune system. Immuno-biological cancer therapy plays an importantrole in strengthening body immunological surveillance function and killing remainingtumor cells in the body. This paper investigates the role of DC/CIKimmuno-biological cancer therapy in maintenance therapy of advanced non-small celllung cancer (NSCLC). To observe the effectiveness and security in advancednon-small-cell lung cancer (NSCLC) with DC/CIK maintenance treatment, so ascan provide more effective method for the treatment of advanced-stage NSCLC.Methods: patients in Ⅲb or Ⅳ stage diagnosed with pathology or cytologyexamination in Shandong Tumor Hospital from September2009to October2010were collected. They reached SD or over after chemotherapy of4cycles of two-drugregimen with platinum (docetaxel+cis-platinum, Gemcitabine+carboplatin,Gemcitabine+cis-platinum). Using random access method divided into the treatmentgroup and control group and each group has30cases. One group was treated withDC/CIK immuno-biological cancer therapy, and the other was taken as a control group. Blood samples were collected from the patients after14days from thechemotherapy. Lymphocytes were separated from blood samples and cultured in vitroand then applied to the patients (DC subcutaneous injection, CIK intravenousreinjection). One cycle took28days. The control group: regularly reviewed andfollowed-up: being reviewed and evaluated at least once a month until diseaseprogressed. All the patients in the treatment group have completed one cycle oftreatment. According to estimation of statistical sample size, the samples comply withthe requirements of curative effect evaluation. At last, cancer progression time andtoxicity reaction of the two groups were evaluated.Results: DC/CIK could extend PFS (3.20months [95%CI2.94–3.50] vs2.56months [95%CI2.39-2.73]; p<0.05). The OS was respectively9.8months and9.5months(p＞0.05). In the treatment group, the OS of squamous carcinoma andadenocarcinoma was respectively9.5months and10.1months(p＞0.05). In thetreatment group, the proportion of NK cells, T-cell subgroups CD3+、CD4+、CD8+and NK cell had a significant change before and after treatment. The liver and kidneyfunction and blood routine of the treatment group were within the normal range beforeand after treatment. In treatment group, one case suffered from chest distress, threecases suffered from acratia, and four cases suffered from pyrexia. ECOG performancestatus and immune indexes had significantly improved.Conclusion:1. DC/CIK can significantly improve patients with advanced non-small cell lungcancer quality of life.2. DC/CIK can improve advanced non-small-cell lung cancer patients with PFS.3DC/CIK can increase the number of peripheral blood CD3CD4and NK cellsof advanced non-small-cell lung cancer patients and improve the immune function ofpatients. 4. No adverse reaction occurs before and after treatment with DC/CIK Intreatment group.5. The effect of treatment with DC/CIK had no relationship between pathologicaltype.